3 "Overlooked" Biotech Stocks to Watch Now

NASDAQ: SGEN | Seattle Genetics, Inc. News, Ratings, and Charts

SGEN – The biotech stocks focused on the coronavirus have been all the rage. But what it leaves behind are other attractive growth opportunities that are trading at more reasonable valuations. That’s why you need to check out SGEN, CYTK and FBIO.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Biotech stocks are all the rage these days, largely because of the push for a coronavirus vaccine.  However, there are plenty of biotech stocks worth your attention aside from the companies attempting to solve the coronavirus puzzle.  Savvy investors will expand their scope to consider biotechs outside of those that have narrowed their focus on ending the pandemic.

However, there are hundreds of attractive biotech stocks to sort through, many of which are attempting to find cures or treatments for similar maladies. Let’s take a look at three of the more intriguing biotech stocks to help determine if they are worthy of consideration for your portfolio: Seattle Genetics, Cytokinetics and Fortress Biotech.

Seattle Genetics (SGEN)

Antibodies are the talk of the land as the coronavirus spreads throughout the United States.  SGEN relies on antibody therapies to treat autoimmune diseases as well as cancer.  The company’s Adcetris drug has been approved for use in the fight against Hodgkin lymphoma.  SGEN’s Padcev drug is used to treat bladder cancer.  The company’s breast cancer drug, Tukysa, is also poised to be a money-maker.

SGEN revenue is up more than 20% on a year-over-year basis.  The analysts have set a high target of $246 for the stock with 12 recommending it as a buy, four advising investors to hold and only one advising investors sell.  The POWR Ratings have SGEN ranked 22nd out of 336 Biotech stocks.  Take a close look at the POWR Components and you will find there are no chinks in SGEN’s armor.  The company has As across the board, making it a true POWR Ratings superstar.

Cytokinetics (CYTK)

Cardiovascular disease and cancer are the top causes of death.  However, the silver lining to the threat of heart disease and the “Big C” is we can make money from their treatment and prevention.  CYTK presents such an opportunity.  This biopharmaceutical business is zeroed in on creating small molecule therapies to treat cancer, cardiovascular disease and ALS.  At the moment, CYTK’s top drug candidate, tirasemtiv, has earned orphan drug designation along with fast-track status by the Food and Drug administration.

The POWR Ratings have CYTK ranked 59th out of more than 330 Biotech stocks.  CYTK aces every single POWR Component but for its Buy & Hold Grade.  The average analyst price target for the stock is in excess of $30, meaning there is nearly 45% upside potential.  The high forecast for the stock is $35.  All in all, five analysts recommend buying the stock while none recommend holding or selling.

The FDA is expediting the company’s top drug candidate, omecamtiv mecarbil.  The aim of this treatment is to assist patients saddled with heart issues better handle reduced ejection fraction.  This is an important step in the right direction for CYTK as more than 60 million people across the globe are impacted by heart failure.  The number of people with heart problems will only continue to increase as the baby boomer age cohort moves through its golden years.

Fortress Biotech (FBIO)

Chances are you or someone in your family will be diagnosed with cancer or an inflammatory disease down the line.  Biotech companies such as FBIO are hard at work developing pharmaceutical solutions for these maladies and bringing them to market.  Once known as Coronado Biosciences, FBIO’s novel immunotherapy agents will undoubtedly be in demand for decades, if not centuries into the future.

It is particularly interesting to note the analysts’ average price target for FBIO is $8.50, meaning there is more than 160% upside.  The low forecast for the stock is $6.  The POWR Ratings have FBIO ranked in the top 20 of more than 330 stocks in the Biotech space.  The stock has As in every POWR Rating component without exception.

Furthermore, FBIO has earnings per share growth of 16% on an annual basis.  The company’s revenue was up nearly 40% last year.  Though FBIO is not the biggest name in the biotech sector, its analyst price targets and solid POWR Ratings certainly warrant investor attention.

Want More Great Investing Ideas?

9 “BUY THE DIP” Growth Stocks for 2020

Bull Market or Bull S#*t? How to trade today’s stock market bubble and prepare for the return of the bear market.

7 “Safe-Haven” Dividend Stocks for Turbulent Times


SGEN shares . Year-to-date, SGEN has gained 31.66%, versus a -2.69% rise in the benchmark S&P 500 index during the same period.

About the Author: Patrick Ryan

Patrick Ryan has more than a dozen years of investing experience with a focus on information technology, consumer and entertainment sectors. In addition to working for StockNews, Patrick has also written for Wealth Authority and Fallon Wealth Management. More...

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
SGENGet RatingGet RatingGet Rating
CYTKGet RatingGet RatingGet Rating
FBIOGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NYSE: TSM | Taiwan Semiconductor Manufacturing Company Ltd. News, Ratings, and Charts

3 Semiconductor Stocks Set To Rise

The shift to remote work has resulted in increased demand for semiconductors. Taiwan Semiconductor (TSM), ASML (ASML), and Broadcom (AVGO are set to soar.
NASDAQ: AMGN | Amgen Inc. News, Ratings, and Charts

3 Top Biotech Stocks for July

The biotech sector is one of the obvious winners of the coronavirus. Amgen (AMGN), Vertex (VRTX), and Seattle Genetics (SGEN) are the top stock picks for July.
NASDAQ: TSLA | Tesla, Inc. News, Ratings, and Charts

3 Stocks That Are Up More Than 100% This Year

Tesla (TSLA), Zoom (ZM) and Shopify (SHOP) are flying high this year. Find out what’s driving up their prices.
NYSE: ORCL | Oracle Corporation  News, Ratings, and Charts

4 Dividend Stocks to Buy if There is a Second Market Crash

The coronavirus has yet to subside in the US and there are fears about a second wave. Oracle (ORCL), Eli Lilly (LLY), EBay (EBAY) and CoreSite Realty (COR) are four dividend stocks that could be a smart investment if the market sours again.
NYSE: GDX | VanEck Vectors Gold Miners ETF News, Ratings, and Charts

3 Gold Miners To Buy in July

As gold nears all-time highs, Kirkland Lake Gold (KL), Anglogold Ashanti (AU), and Alamos Gold (AGI) should be on your watchlist

Read More Stories

More Seattle Genetics, Inc. (SGEN) News View All

Event/DateSymbolNews DetailStart PriceEnd PriceChangePOWR Rating
Loading, please wait...
View All SGEN News